文献速递炎症性肠病

托法替布治疗溃疡性结肠炎患者的缓解维持

Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-10-09

该研究基于OCTAVE Sustain和OCTAVE Open项目,分析142例经52周维持治疗达缓解的中重度溃疡性结肠炎患者,在开放标签长期扩展研究中接受托法替布5 mg每日两次治疗。结果显示12个月时68.3%维持缓解,36个月时50.4%维持缓解,未发现新的安全性风险。

要点

  • 142例中重度UC缓解患者接受托法替布5 mg每日两次长期治疗。
  • 治疗12个月时68.3%维持缓解,36个月时50.4%维持缓解。
  • 长达36个月暴露未发现新的安全性风险。

核心结论

  • 疗效终点维持至36个月,无论既往托法替布剂量如何,包括在OCTAVE Open入组时从10 mg减至5 mg每日两次的患者。
  • 未发现新的安全性风险。

研究设计与样本

  • 3期、多中心、开放标签、长期扩展研究(OCTAVE Open),纳入完成52周3期维持研究(OCTAVE Sustain)的中重度UC患者。
  • 分析142例在OCTAVE Sustain中经托法替布治疗达缓解、并在OCTAVE Open中接受托法替布5 mg每日两次的患者。

主要发现

  • 在OCTAVE Open中接受托法替布5 mg每日两次治疗12个月后,68.3%的患者处于缓解,73.9%有内镜下改善,77.5%有临床应答。
  • 第36个月时,50.4%的患者处于缓解,55.3%有内镜下改善,56.0%有临床应答。
  • 托法替布5 mg每日两次的安全性特征显示,截至36个月的长期暴露未发现新的安全性风险。

关键数值与推荐

  • 缓解基于总Mayo评分评估。
  • 疗效评估包括缓解、内镜下改善、临床应答和部分Mayo评分,随访至OCTAVE Open第36个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib in patients with moderate to severe UC, up to 1 year, have been reported. We investigated maintenance of efficacy in patients in remission after 52 weeks of maintenance treatment in the pivotal phase 3 study (OCTAVE Sustain); these patients received open-label, long-term treatment with tofacitinib 5 mg twice daily. METHODS: Patients with moderate to severe UC who completed a 52-week, phase 3 maintenance study (OCTAVE Sustain) were eligible to enroll into the ongoing, phase 3, multicenter, open-label, long-term extension (OCTAVE Open). We analyzed data from 142 patients who were in remission following tofacitinib treatment in OCTAVE Sustain who received tofacitinib 5 mg twice daily during OCTAVE Open. We assessed efficacy (including remission [based on total Mayo score], endoscopic improvement, clinical response, and partial Mayo score up to month 36 of OCTAVE Open) and safety data. RESULTS: After 12 months of tofacitinib 5 mg twice daily in OCTAVE Open, 68.3% of patients were in remission, 73.9% had endoscopic improvement, and 77.5% had a clinical response. At month 36, 50.4%, of the patients were in remission, 55.3% had endoscopic improvement, and 56.0% had a clinical response. The safety profile of tofacitinib 5 mg twice daily revealed no new safety risks associated with long-term exposure up to 36 months. CONCLUSIONS: Efficacy endpoints were maintained for up to 36 months, regardless of prior tofacitinib dose, including patients who reduced from tofacitinib 10 mg to 5 mg twice daily upon OCTAVE Open entry. No new safety risks were identified. ClinicalTrials.gov: OCTAVE Sustain (NCT01458574); OCTAVE Open (NCT01470612).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Colombel JF, Osterman MT, Thorpe AJ, et al. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 33039585. doi:10.1016/j.cgh.2020.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。